GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » Profitability Rank

Dyne Therapeutics (Dyne Therapeutics) Profitability Rank : 1 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Dyne Therapeutics Profitability Rank?

Dyne Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Dyne Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Dyne Therapeutics's Piotroski F-Score is 3.


Competitive Comparison of Dyne Therapeutics's Profitability Rank

For the Biotechnology subindustry, Dyne Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyne Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Dyne Therapeutics's Profitability Rank falls into.



Dyne Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Dyne Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Dyne Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-69.157 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Dyne Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Dyne Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Dyne Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyne Therapeutics (Dyne Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1560 Trapelo Road, Waltham, MA, USA, 02451
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
Executives
Dirk Kersten director, 10 percent owner C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Joshua T Brumm director, officer: See Remarks ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Jonathan Mcneill officer: See Remarks C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Oxana Beskrovnaya officer: See Remarks C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Richard William Scalzo officer: See Remarks 25 ALBERTA LANE, HOLLISTON MA 01746
Wildon Farwell officer: Chief Medical Officer C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Susanna Gatti High officer: Chief Operating Officer 75 LORIMER ROAD, BELMONT MA 02141
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Jason P Rhodes director, 10 percent owner C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Carlo Incerti director FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Romesh Subramanian 10 percent owner, officer: Chief Scientific Officer C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Cureduchenne Ventures, Llc 10 percent owner 1400 QUAIL STREET, SUITE 110, NEWPORT BEACH CA 92660